Cholinergic Enhancement as Treatment for Nicotine Addiction

增强胆碱能治疗尼古丁成瘾

基本信息

批准号：
8582890
负责人：
Mehmet Sofuoglu
金额：
$ 17.56万
依托单位：
YALE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-07-01 至 2015-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8582890
关键词：
Abstinence Acetylcholine Acetylcholinesterase Acetylcholinesterase Inhibitors Agonist Alzheimer&apos s Disease Attention Attenuated Cause of Death Cessation of life Cholinergic Receptors Cholinesterase Inhibitors Cigarette Clinical Research Clinical Trials Cognitive Cotinine Developed Countries Development Dose Double-Blind Method Environment Enzymes Future Galantamine Goals Human Intravenous Laboratories Lead Measures Modeling Muscarinics Neurotransmitters Nicotine Nicotine Dependence Nicotinic Receptors Outcome Measure Patient Self-Report Performance Pharmaceutical Preparations Pharmacotherapy Phase Pilot Projects Placebo Control Placebos Randomized Safety Self Administration Severities Smoker Smoking Smoking Behavior Study Subject Therapeutic Titrations Tobacco Dependence Visit Withdrawal Work brief intervention cholinergic cigarette smoking craving efficacy testing improved nicotine replacement novel preclinical study premature prevent public health relevance response satisfaction smoking cessation transmission process treatment duration

项目摘要

DESCRIPTION (provided by applicant): Nicotine addiction continues to be the main cause of preventable death in developed countries, with an estimated 435,000 premature deaths in the U.S. alone. Despite the availability of effective pharmacotherapies, 70 to 90% of smokers resume smoking within a year of treatment. Accordingly, the development of novel and effective nicotine dependence pharmacotherapies continues to be an important goal. In an effort to identify novel therapies for nicotine addiction, we recently conducted a pilot study using galantamine (GAL) as a treatment for smokers. GAL enhances cholinergic transmission by inhibiting acetylcholinesterase, the enzyme that breaks down acetylcholine. Acetylcholine is the endogenous neurotransmitter for the nicotinic and muscarinic type cholinergic receptors. GAL also directly potentiates the activation of nicotinic acetylcholine receptors. In our study, a 4-da GAL treatment (8 mg/day) attenuated some of the subjective effects from intravenous (IV) nicotine when compared with placebo. Furthermore, GAL reduced the craving for cigarettes and improved performance on a Go No-Go task. These findings, together with other preclinical and clinical studies, support the potential efficacy of GAL as a treatment for nicotine addiction. To extend our preliminary findings, we propose a double-blind, placebo-controlled, between-subjects study that will randomize 72 smokers to receive GAL (8 mg/day, 16 mg/day), or a placebo treatment for a total of 7 weeks. Following 2 weeks of dose titration, smokers will complete a laboratory session that measures smoking behavior. In the subsequent 4-week treatment phase, smokers will continue their assigned medication and will attempt to quit smoking. During this phase, measures of smoking behavior (self-report and cotinine), withdrawal severity, and cognitive performance will be obtained. To our knowledge, this is the first study examining the therapeutic potential and the mechanism of action of GAL for the treatment of tobacco dependence.

描述（由申请人提供）：尼古丁成瘾仍然是发达国家可预防死亡的主要原因，仅在美国估计就有 435,000 人过早死亡。尽管有有效的药物疗法，但 70% 至 90% 的吸烟者在治疗一年内恢复吸烟。因此，开发新颖且有效的尼古丁依赖性药物疗法仍然是一个重要目标。为了寻找治疗尼古丁成瘾的新疗法，我们最近进行了一项试点研究，使用加兰他敏 (GAL) 作为吸烟者的治疗方法。 GAL 通过抑制乙酰胆碱酯酶（分解乙酰胆碱的酶）来增强胆碱能传递。乙酰胆碱是烟碱型和毒蕈碱型胆碱能受体的内源性神经递质。 GAL 还直接增强烟碱乙酰胆碱受体的激活。在我们的研究中，与安慰剂相比，4 天 GAL 治疗（8 毫克/天）减轻了静脉注射 (IV) 尼古丁的一些主观影响。此外，GAL 减少了对香烟的渴望，并提高了 Go-No-Go 任务的表现。这些发现与其他临床前和临床研究一起支持 GAL 作为尼古丁成瘾治疗的潜在功效。为了扩展我们的初步研究结果，我们提出了一项双盲、安慰剂对照、受试者间研究，该研究将随机 72 名吸烟者接受 GAL（8 毫克/天、16 毫克/天）或安慰剂治疗，总共 7 次。几周。两周剂量调整后，吸烟者将完成测量吸烟行为的实验室课程。在随后的 4 周治疗阶段，吸烟者将继续接受指定的药物治疗并尝试戒烟。在此阶段，将获得吸烟行为（自我报告和可替宁）、戒断严重程度和认知表现的测量结果。据我们所知，这是第一项研究 GAL 治疗烟草依赖的治疗潜力和作用机制的研究。